Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $50.00 target price on the stock.

Several other research analysts also recently commented on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Morgan Stanley reaffirmed an “equal weight” rating and set a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Finally, Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Trading Down 0.2 %

NASDAQ:GMAB opened at $22.15 on Wednesday. The firm’s 50 day moving average is $21.31 and its 200 day moving average is $24.22. Genmab A/S has a 12 month low of $19.85 and a 12 month high of $31.97. The stock has a market capitalization of $14.66 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 0.63 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The firm had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter in the previous year, the company posted $0.47 EPS. Research analysts predict that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently bought and sold shares of GMAB. GAMMA Investing LLC raised its holdings in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Genmab A/S by 43.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares in the last quarter. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its position in Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.